Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday

Key Points

• Verrica Pharmaceuticals is expected to report Q2 2026 earnings after market close on August 6. Analysts project a loss of $0.41 per share and revenue of approximately $5.73 million.
• In the prior quarter, Verrica reported a $0.41 per-share loss, beating estimates by $0.18, while revenue of $5.02 million exceeded expectations. The company remains unprofitable, with a negative net margin of 47.97%.
• Analyst sentiment is mixed: the stock has an overall “Hold” consensus and a $14.50 price target, despite ratings ranging from “Buy” to “Sell.” VRCA recently traded at $5.22, well below its 52-week high of $9.82.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) is anticipated to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Verrica Pharmaceuticals to post earnings of ($0.41) per share and revenue of $5.7330 million for the quarter. Individuals can check the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative return on equity of 1,077.78% and a negative net margin of 47.97%.The company had revenue of $5.02 million for the quarter, compared to analyst estimates of $4.51 million. On average, analysts expect Verrica Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Verrica Pharmaceuticals Price Performance

VRCA stock opened at $5.22 on Friday. The stock has a market capitalization of $89.68 million, a price-to-earnings ratio of -5.07 and a beta of 1.47. The company has a quick ratio of 1.98, a current ratio of 2.10 and a debt-to-equity ratio of 0.03. Verrica Pharmaceuticals has a 52-week low of $3.28 and a 52-week high of $9.82. The stock's fifty day simple moving average is $5.86 and its 200-day simple moving average is $6.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VRCA. XTX Topco Ltd purchased a new stake in Verrica Pharmaceuticals during the fourth quarter valued at about $122,000. Quadrature Capital Ltd purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter worth about $99,000. Man Group plc purchased a new position in shares of Verrica Pharmaceuticals in the 4th quarter worth about $94,000. Squarepoint Ops LLC acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $276,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Verrica Pharmaceuticals in the 4th quarter valued at about $188,000. Institutional investors and hedge funds own 42.45% of the company's stock.

Wall Street Analyst Weigh In

VRCA has been the topic of several recent analyst reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Zacks Research upgraded Verrica Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday, May 11th. HC Wainwright assumed coverage on shares of Verrica Pharmaceuticals in a research note on Tuesday, May 26th. They set a "buy" rating and a $12.00 price objective for the company. Finally, Wall Street Zen lowered shares of Verrica Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, July 25th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Verrica Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $14.50.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica's approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.